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Abstract
Background: Cyclin D1 which is associated with cell cycle regulation is solidly established as an oncogene with an important 
pathogenetic role in breast carcinomas.
Objectives: The aim of  this study was to relate the Cyclin D1 protein overexpression with the amplification of  its gene CCND1 
in Estrogen Receptors (ER) positive breast carcinomas, in order to investigate the prognostic effect of  their aberrations in rela-
tion to ER status, also to correlate the Cyclin D1 overexpression with other prognostic parameters.
Materials and methods: Chromogenic in situ hybridization (CISH) was used to identify CCND1 amplification on forma-
lin-fixed paraffin-embedded invasive ductal carcinoma, in which immunohistochemistry (IHC) had previously been performed 
in order to evaluate the pathological relevance of  Cyclin D1 overexpression in human breast cancer (n = 138).
Results: CCND1 amplification was identified in 17/138 (12.3%) tumors and 78/138 (56.5%) tumors have overexpressed Cyclin 
D1. A significant correlation was identified between CCND1 amplification and Cyclin D1 overexpression (P < 0.001) and both 
Cyclin D1 and CCND1 were related with ER expression.
Conclusion: Our results show a significant correlation between Cyclin D1 overexpression and CCND1 amplification. Over-
expression of  Cyclin D1was observed in high proportion of  breast cancer which should be considered for routine diagnosis.
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Introduction
Gene amplification is a frequent device leading to the 
overexpression of  oncogenes in human cancers1. Cyclin 
D1 is the product of  the CCND1 gene located on chro-
mosome 11q132. Cyclin D1, an important regulator of  
the cell cycle,3,4 has been reported in 40% to 90% of  in-
vasive breast cancer cases4-6 and its gene has been found 
amplified in 15–20% of  breast cancers7-9. These facts are 
well established and indicate that mechanisms other than 
gene amplification are responsible for deregulation of  
the protein. In addition to its role in cell cycleregulation, 
Cyclin D1 can regulate the growth of  estrogen respon-
sive tissues by activating the estrogen receptor (ER) in 
a ligand-independent fashion10. The induction of  Cyclin 
D1 in breast cancer cell lines generate an increase in the 
number of  cells progressing through G1 and accelerate 
transition from G1 to S phase, indicating that Cyclin D1 
is rate-restrictive for progress through G1 phase11. This 
rate-limiting step in cell cycle progression is regulated by a 
number of  mechanisms including Cyclin D1 abundance; 
consequently, deregulation of  Cyclin D1 gene expression 
or function is a probable contributor to loss of  normal 
cell cycle control during carcinogenesis12.
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In this study, Cyclin D1 overexpression was detected by 
immunohistochemistry and its gene amplification was 
detected by chromogenic in situ hybridization (CISH). 
Overexpression of  Cyclin D1 protein was also investigat-
ed in combination with prognostic marker. The aims of  
the present study were to determine in the first part, the 
correlation between Cyclin D1 overexpression and other 
prognostic parameters, and in second part, to correlate 
the Cyclin D1 overexpression with the CCND1 amplifi-
cation in breast carcinomas.
Materials and methods
The study material consists of  138 invasive ductal breast 
carcinomas (IDC) from patients diagnosed between Jan-
uary 2011 and September 2015. All patients’ tumors were 
collected from the Regional Military University Hospital. 
Patient characteristics are summarized in Table 1.
Table 1: Patient and tumor clinicopathological characteristics 
 
Characteristics Number of patients (%) 
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Clinicopathological characteristics of  the patients like 
age, SBR grade,tumor size and lymph node status were 
extracted from the pathology reports. For immunohis-
tochemical analysis, paraffin sections were mounted on 
APES (2% 3'-aminopropyltriethoxysilane) coated slides. 
A monoclonal Mouse antibody Anti-Human Cyclin D1 
clone DCS-6, DAKO (provided in liquid form as tis-
sue culture supernatant in 0.05 mol/L Tris-HCl, pH 7.6 
and 0.015 mol/L sodium azide) was used. The indirect 
avidin-biotin immunoperoxidase technique was used to 
demonstrate antibody binding sites. Finally, the sections 
were lightly counterstained in hematoxylin. Scoring of  
the Cyclin D1, Ki-67, ER and progesterone receptor (PR) 
reactivity, was performed by using the Allred method13, 
which classifies tumors into three groups: negative/weak 
(scores 0–2), moderate (scores 3–5) and strong (scores 
6–8).
To analyze the amplification of  CCND1, we used chro-
mogenic in situ hybridization (CISH), in which paraf-
fin-embedded tissue sections were fixed in neutral buff-
ered formalin for 12-24 hours before use. Tissue sections 
(4-5 μm thickness) were mounted on Superfrost/Plus mi-
croscope slides. Deparaffinized slides were heated above 
98°C for 15 min. in tissue heat pre-treatment solution and 
incubated for enzyme digestion for 10 min. After dena-
turation and hybridization, CISH staining results were vi-
sualized with a standard brightfield microscope and a 40x 
dry lens. The presence of  ≥5 individual signals, within 
the nuclei of  a single cell is indicative of  positive reactiv-
ity. The statistical analysis was performed using the IBM 
SPSS Advanced 20.0 statistical software, reference: 5725-
A54. Correlations of  Cyclin D1 and CCND1 to other 
clinicopathologic parameters were evaluated using Pear-
son’s correlation test (r). P value <0.05 was considered as 
significant.
Results
The clinicopathological characteristics of  the patients are 
mentioned in table 1. The grade SBR II was dominant 
(63.1%). Tumor sizes exceed 2 cm in 92% of  the patients, 
and 60.9% had positive lymph nodes. The immunohis-
tochemical staining showed overexpression of  ER and 
PR in 79.7% and 68.8% of  cases respectively. Ki-67 was 
overexpressed in 66.7% of  tumors and Cyclin D1 overex-
pression was observed in 78 (56.5%) cases. The CCND1 
gene was amplified in 17 (12.3%) cases.
The results of  the clinicopathological characteristics of  
the tumors in relation to the expression of  Cyclin D1 are 
shown in Table 2. Cyclin D1 expression was found in 78 
(56.5%) cases, whose 52.6% expressed it moderately and 
47.4% were strongly positive. The majority of  cases, 53 
cases (67.9%) were in the ≥50 year age group. The max-
imum number of  cases (51/78) 65.4% had grade SBR 
II. (48/78) 61.5% cases had positive lymph nodes and 
70.5% of  tumors were >2 cm. There was no significant 
correlation between overexpression of  Cyclin D1 and age 
of  patients (r = 0.161/ P = 0.060), grade SBR (r = -0.05/ 
P = 0.518), lymph node status (r = -0.01/ P = 0.833), 
size of  tumors (r = 0.11/ P = 0.186). There was a signif-
icant correlation between high Cyclin D1 expression and 
hormone receptors including ER and PR (r = 0.52/ P = 
<0.001 and r = 0.26/ P = 0.002). Cyclin D1 overexpres-
sion was significantly correlated with proliferation marker 
Ki-67 (r = 0.19/ P = 0.022).
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The results of  the clinicopathological parameters in rela-
tion to the CCND1 status are shown in Table 3. CCND1 
amplification was found in 17 (12.3%) cases whose 14 
cases presented >10 copies of  the gene present per nu-
cleus in >50% cancer cells. CCND1 was correlated with 
hormone receptor positivity ER (r = 0.28/ P = 0.003) 
and PR (r = 0.22/ P = 0.030) while there was no cor-
relation with proliferation marker Ki-67 (r = 0.15/ P = 
0.080). CCND1 amplification was not significantly relat-
ed in our study to age of  patients (r = -0.11/ P = 0.202), 
SBR grade (r = -0.07/ P = 0.361), lymph node status (r = 
-0.01/ P = 0.855) and tumors size (r = 0.05/ P = 0.559).
Parameters
Correlation of  Cyclin D1 expression with CCND1 
amplification:
Gene amplification of  CCND1 was observed in moder-
ate and strong Cyclin D1 expression subgroups (Table 
4). Among the 17 patients with amplification of  CCND1 
(>5 copies), 13 (76.5%) showed a strong expression of  
Cyclin D1, whereas 4/17 showed moderate expression. 
Tumors with non-amplified CCND1 gene were also 
observed in moderate and strong sub-groups with low 
frequencies corresponding to 30.6% and 19.8% respec-
tively. A good association was found between CCND1 
amplification and Cyclin D1 overexpression (Table 4, P 
< 0.001). This correlation was very high (r = 0.42 / p < 
0.0001) in hormone receptor-positive tumors.
Table 2: Correlation of Cyclin D1 expression with clinicopathological parameters 
 
Parameters Negative/weak 
Cyclin D1 expression 
Moderate 
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Table 3: Correlation of CCND1 amplification with clinicopathological parameters 
 
Parameters CCND1 non-amplified CCND1 amplified r/P-values 



























Tumors size (cm) 
< 2 cm 
2 -5 cm 



































Parameters Negative/weak Moderate Strong r/P-values
CCND1 gene status 0.42/<0.001
Non-amplified (< 5 copies) 60 (49.6%) 37 (30.6%) 24 (19.8%)
Amplified (>5 copies) 0 4 (23.5%) 13 (76.5%)
Table 4: Correlation of Cyclin D1 expression with CCND1 amplification.
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Discussion
In the present study, we have firstly examined the Cy-
clin D1 expressions by IHC and correlate it with ER, PR, 
Ki-67 and other clinicopathological parameters, on the 
other hand, we examined by CISH the copies number of  
CCND1 gene in invasive ductal breast cancer in relation 
to Cyclin D1 protein expression.
Cyclin D1 is necessary for the normal development of  the 
breast and dysregulated expression stimulates aberrant 
mammary epithelial proliferation14. In the current study, 
Cyclin D1 overexpression was found in 56.5% of  cases 
which is in concordance with many of  the similar stud-
ies15-17 who showed that Cyclin D1 was overexpressed in 
60% - 63.4% of  breast carcinomas. We found that Cyclin 
D1 was significantly correlated with ER+ breast cancer, 
these results is comparable to other study6,18 on invasive 
breast carcinoma where they found a positive correla-
tion of  Cyclin D1 overexpression with ER expression. 
This can be explained by the positive regulation of  ER 
by Cyclin D1 in breast cancer cell lines where Cyclin D1 
has been shown to join directly and activate the estrogen 
receptor alpha (ER) in a cdk- and pRB-independent fash-
ion10,19. This finding, that overexpressed Cyclin D1 can 
activate the ER independently, has the potential to add 
a crucial dimension to our understanding of  mammary 
carcinogenesis20-22.  In the current study, we found a sig-
nificant correlation between Cyclin D1 and Ki-67, which 
is linked to a more aggressive tumor phenotype, these re-
sults are is in accordance with a previous study23 who be-
lieve that tumors with overexpression of  Cyclin D1 have 
a higher growth potential and favor the progression of  
the cell cycle more easily resulting in the overexpression 
of  Ki-67.
The other clinicopathological parameters like SBR grade, 
tumor size and lymph nodes status were no correlated 
with Cyclin D1 overexpression in our study; this is in 
agreement with previous studies18,24,25 demonstrating that 
no significant association between these parameters and 
Cyclin D1 overexpression.
Given that amplification of  CCND1 is one of  the rea-
sons for Cyclin D1 overexpression in breast cancer, we 
have tried to correlate them. We found an excellent cor-
relation between CCND1 amplification and Cyclin D1 
overexpression, particularly in ER+ tumors; this result is 
in agreement with many previous studies6,15,16,18.
Conclusion
Our results confirmed a high correlation of  Cyclin D1 
expression and CCND1 amplification in ER+ breast can-
cer; hence it would be useful to identify a subset of  pa-
tients with ER+ breast cancer for which CCND1 amplifi-
cation should be considered for diagnosis and treatment.
Our results also showed that high expression of  Cyclin 
D1 is not always resulting to CCND1 amplification sug-
gesting that its association with other clinicopathological 
parameters is also responsible for this overexpression. 
Finally, because of  its established role as a major human 
oncogene, direct targeting of  the Cyclin D1 protein or 
CCND1 gene may prove successful.
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